- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ENLIVEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.08. | Enliven Therapeutics, Inc Q2 Loss Climbs | 1 | RTTNews | ||
| 13.08. | Enliven Therapeutics GAAP EPS of -$0.49 beats by $0.04 | 1 | Seeking Alpha | ||
| 13.08. | Enliven Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 13.08. | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update | 146 | PR Newswire | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks... ► Artikel lesen | |
| 25.06. | Enliven Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.06. | TD Cowen bekräftigt Kaufempfehlung für Enliven Therapeutics-Aktie | 1 | Investing.com Deutsch | ||
| 20.06. | TD Cowen reiterates buy rating on Enliven Therapeutics stock | 1 | Investing.com | ||
| 16.06. | Goldman Sachs initiates Enliven Therapeutics stock with Buy rating | 1 | Investing.com | ||
| 13.06. | Enliven Therapeutics prices $200 million public offering | 1 | Investing.com | ||
| 13.06. | Enliven Therapeutics stock falls after pricing capital raise of $200M via securities offering | 1 | Seeking Alpha | ||
| 13.06. | Enliven Therapeutics announces $200 million public offering | 5 | Investing.com | ||
| 13.06. | Enliven Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.06. | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress | 300 | PR Newswire | Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen | |
| 30.05. | Mizuho erhöht Kursziel für Enliven Therapeutics-Aktie auf 41 US-Dollar | 1 | Investing.com Deutsch | ||
| 16.05. | BTIG raises Enliven Therapeutics stock target to $45 | 1 | Investing.com | ||
| 15.05. | Enliven Therapeutics GAAP EPS of -$0.57 beats by $0.01 | 1 | Seeking Alpha | ||
| 15.05. | Enliven Therapeutics stock target raised to $40 at H.C. Wainwright | 1 | Investing.com | ||
| 14.05. | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update | 381 | PR Newswire | Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June
EHA abstract reported cumulative MMR rate... ► Artikel lesen | |
| 14.05. | Enliven reports positive Phase 1 trial data for ELVN-001 in CML | 1 | Investing.com | ||
| 14.05. | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress | 379 | PR Newswire | Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,796 | -0,73 % | UNGLAUBLICHE Sondermeldung bei Valneva Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen und reagieren! | ||
| BIOFRONTERA | 2,950 | +6,12 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG: Neue Prognose | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG: Neue Prognose
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
Biofrontera AG: Biofrontera AG: Neue Prognose
Leverkusen (pta000/01.08.2025/12:00... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 50,000 | +1,63 % | CRISPR Therapeutics AG: CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025 | ||
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| DENALI THERAPEUTICS | 11,380 | +1,70 % | Denali Therapeutics Inc.: Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights | Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launchDNL126 accelerated approval... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,816 | +0,59 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent... ► Artikel lesen | |
| CELLECTIS | 2,720 | +5,84 % | Cellectis S.A. - S-8, Securities to be offered to employees in employee benefit plans | ||
| AGIOS | 31,000 | 0,00 % | Agios Pharmaceuticals, Inc.: Agios' PYRUKYND (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia | First regulatory approval for PYRUKYND in thalassemia, evaluated under SFDA's Breakthrough Medicines Program Agios partnered with NewBridge Pharmaceuticals, a regional specialty company focused on... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,622 | +1,34 % | Voyager Therapeutics Alzheimer's Portfolio And ALPL NeuroShuttle Underscore Platform Momentum: Analyst | ||
| UNIQURE | 12,950 | +2,70 % | Mizuho reiterates uniQure stock rating, sees buying opportunity amid drop | ||
| ENZO BIOCHEM | 0,388 | 0,00 % | Battery Ventures Completes Take-Private of Enzo Biochem | Apter joins as CEO to support the next stage of growth for the life-science reagents platform
BOSTON--(BUSINESS WIRE)--Battery Ventures, a global, technology-focused investment firm, announced the... ► Artikel lesen | |
| TECTONIC THERAPEUTIC | 16,590 | 0,00 % | Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025 | Data confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved... ► Artikel lesen | |
| SCILEX | 25,700 | 0,00 % | Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc. | Denali's registration statement on Form S-4 declared effective by the Securities and Exchange CommissionExtraordinary general meeting of Denali Capital Acquisition Corp. shareholders to approve the... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 1,150 | 0,00 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation ... | Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee, and in Consultation with the FDA Following an ALLO-647-Related... ► Artikel lesen | |
| NUVATION BIO | 3,145 | 0,00 % | Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer | Sustained durability of responses demonstrated in both TRUST-I and TRUST-II with additional follow-up time TKI-naïve patients in TRUST-I achieved a median progression-free survival of 44.6 months... ► Artikel lesen |
ENLIVEN THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 18,510 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENLIVEN THERAPEUTICS INC finden Sie auf Wallstreet Online.